Regadenoson
From Wikipedia, the free encyclopedia
 |
|
|
Regadenoson
|
|
| Systematic (IUPAC) name | |
| 1-[6-amino-9-[(2R,3R,4S,5R)-3,4-dihydroxy-5- (hydroxymethyl)oxolan-2-yl]purin-2-yl]- N-methylpyrazole-4-carboxamide | |
| Identifiers | |
| CAS number | 875148-45-1 |
| ATC code | ? |
| PubChem | |
| Chemical data | |
| Formula | C15H18N8O5 |
| Mol. mass | 390.354 g/mol |
| Synonyms | 2-[4-[(methylamino)carbonyl]- 1H-pyrazol-1-yl]-adenosine |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Metabolism | ? |
| Half life | ? |
| Excretion | ? |
| Therapeutic considerations | |
| Licence data |
|
| Pregnancy cat. |
C(US) |
| Legal status | |
| Routes | Intravenous |
Regadenoson (INN, codenamed CVT-3146) is an A2A adenosine receptor agonist that is a coronary vasodilator.
It was approved by the United States Food and Drug Administration on April 10, 2008 and it will be marketed under the tradename Lexiscan.[1] It has not yet gained approval in the European Union.
[edit] References
 |
This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |
